Population
Patients with cardiac ischaemic syndromes
Design
Review
Authors
Loading...
Metabolic agents may serve as adjuncts in ischaemic syndromes; leaves open need for dedicated outcome trials.
This review highlights the role of metabolic agents like L-carnitine, trimetazidine, and ranolazine as alternative pharmacological approaches for managing ischaemic heart disease.
Chierchia et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: